Transgenic mouse models have been used extensively to model the cognitive impairments
arising from Alzheimer's disease (AD)-related pathology. However, less is known about the …

Alzheimer's disease (AD) is the most common neurodegenerative disorder worldwide and
causes severe financial and social burdens. Despite much research on the pathogenesis of …

Transgenic mouse models of Aβ amyloidosis generated by knock-in of a humanized Aβ
sequence can offer some advantages over the transgenic models that overexpress amyloid …

Abstract Background Matrix metallopeptidase 9 (MMP9) has been implicated in a variety of
neurological disorders, including Alzheimer's disease (AD), where MMP9 levels are …

Alzheimer's disease (AD) is believed to be triggered by increased levels/aggregation of β-
amyloid (Aβ) peptides. At present, there is no effective disease-modifying treatment for AD …

Behavioural and psychological symptoms of dementia (BPSD) are presented in 95% of
Alzheimer's Disease (AD) patients and are also associated with neurotrophin deficits. The …

Antipsychotics increase the risk of death in elderly patients with Alzheimer's disease (AD).
Thus, there is an immediate need for novel therapies to treat comorbid psychosis in AD …

Background: The prevalence of Alzheimer's disease (AD) is greater in women compared to
men, but the reasons for this remain unknown. This sex difference has been widely …

Neuropsychiatric symptoms, such as anxiety and depression often appear early in patients
with Alzheimer's disease (AD), and a comorbid, anxiety-like phenotype is also found in …

Most patients with Alzheimer's disease (AD) develop neuropsychiatric symptoms (NPS)
alongside cognitive decline, and apathy is one of the most common symptoms. Few …